MaxCyte, Inc. Presentations at Upcoming Virtual IR Conferences (5929E)
November 09 2020 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5929E
MaxCyte, Inc.
09 November 2020
MaxCyte to Present at Two Upcoming
Virtual Healthcare Investor Conferences
Gaithersburg, MD, 9 November 2020: MaxCyte, Inc. (LSE: MXCT,
MXCL), a global cell-based therapies and life sciences company,
announces today that CEO Doug Doerfler will present an overview of
the company at the Stifel 2020 Virtual Healthcare Conference on
Tuesday, November 17, and at the Jefferies Virtual London
Healthcare Conference on Thursday, November 19. Both presentations
will be accessible on the Company's website, under the Investors
tab.
Stifel 2020 Virtual Healthcare Conference
November 16-18, 2020
MaxCyte presentation: Tuesday, November 17, 10:00 a.m. to 10:30
a.m. (EST)
Jefferies Virtual London Healthcare Conference
November 17-19, 2020
MaxCyte presentation: Thursday, November 19, 1:10 p.m. to 1:40
p.m. (EST)
About MaxCyte
MaxCyte is a clinical-stage global
cell-based therapies and life sciences
company. As the inventors of the
premier cell-engineering enabling
technology, the Company helps bring
the promise of next-generation cell
and gene-editing therapies to life.
The Company's technology is currently
being deployed by leading drug developers
worldwide, including all of the
top ten global biopharmaceutical
companies. MaxCyte licences have
been granted for more than 120 cell
therapy programmes, with more than
90 licensed for clinical use, and
the Company has now entered into
eleven clinical/commercial license
partnerships with leading cell therapy
and gene editing developers. MaxCyte
was founded in 1998, is listed on
the London Stock Exchange (LSE:
MXCT, MXCL) and is headquartered
in Gaithersburg, Maryland, US. For
more information, visit www.maxcyte.com
.
###
Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-com
Mary-Jane Elliott
Chris Welsh
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUWAORROUARUA
(END) Dow Jones Newswires
November 09, 2020 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024
